Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
OSAKA, Japan and TOKYO, Japan, Apr 18, 2022 - (JCN Newswire) - Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.
Hepatitis B is a potentially life-threatening liver disease caused by the hepatitis B virus (HBV). Chronic infection with HBV results in a high risk of death from cirrhosis and liver cancer. About 300 million people are living with chronic hepatitis B infection worldwide, and hepatitis B resulted in an estimated 820,000 deaths in 20191. Although the widespread use of hepatitis B vaccines in infants has considerably reduced the incidence of new chronic HBV infections under the age of 5, the number of new infections by other routes continues to increase2.
Interferon (IFN) and nucleotide analog therapy are currently used in the treatment of hepatitis B. However, treatment with IFN has a high frequency of side effects, and nucleotide analog therapy has a high recurrence rate if treatment is interrupted, so it is necessary to take drugs for a lifetime3. Therefore, the unmet medical need for safe and highly effective drugs that can finally achieve a complete cure for hepatitis B is high.
Isao Teshirogi, President & CEO, Shionogi said: "Shionogi has been engaged in the research and development of infectious diseases for over 60 years. As a leading infectious disease company, we are taking on the challenge of protecting people from the threat of infectious diseases and realizing total care. One company, and even the entire pharmaceutical industry on its own, can only go so far in dealing with a global pandemic like COVID-19. We will further enhance our contribution to global health by integrating NEC's AI technologies while leveraging our strengths."
Nobuhiro Endo, Chairman of the Board, NEC Corporation said: "NEC is committed to our vision of 'Orchestrating a brighter world,' and we are delighted to collaborate with Shionogi to realize this vision through the development of novel treatments for patients. The innovative AI technologies of the NEC Group have the potential to overcome several challenges in what is usually a long and labor-intensive drug discovery process. Through this new partnership with Shionogi, a recognized leader in the field of infectious disease, we aim to maximize the contribution of our AI to accelerate the pace of drug discovery, and thereby to contribute to society."
By fusing Shionogi's drug discovery capability, focused on the infectious disease field, with NEC's expertise in artificial intelligence (AI), the companies will accelerate the progress toward a new therapeutic vaccine. Going forward, the companies will continue to actively expand such joint research into other infectious diseases where unmet medical needs remain.
About Shionogi & Co., Ltd.
Shionogi is committed to "Protect people worldwide from the threat of infectious diseases" as our key focus. We are not limiting ourselves to the research and development of therapeutic medications, but are also focused on the total care of infectious disease, through detection and forecast, prevention, diagnosis, and treating exacerbations, as well as the infection itself. For more information, please visit https://www.shionogi.com/global/en/.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
About NEC OncoImmunity AS
NEC OncoImmunity AS is an AI-driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at https://www.oncoimmunity.com/.
Source: NEC Corporation Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
Fujitsu and Mizuho leverage AI to track trends in humpback whale migration and promote sustainable tourism for Hachijo Island May 21, 2024 11:51 JST
| Hitachi High-Tech and Hitachi have started collaborating on digital transformation of materials development with ITRI, contributing to improvements of Taiwan's industrial standards May 21, 2024 11:01 JST
| MHI Receives Order for Additional 12 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France May 20, 2024 11:36 JST
| Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning May 17, 2024 14:03 JST
| NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud May 17, 2024 11:19 JST
| Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles May 15, 2024 14:30 JST
| Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 15, 2024 11:19 JST
| SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern May 14, 2024 21:54 JST
| DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot May 14, 2024 11:02 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings May 13, 2024 18:32 JST
| Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures May 13, 2024 17:06 JST
| Ogier and TOYOTA GAZOO Racing triumph again May 13, 2024 14:36 JST
| Spa points haul for TOYOTA GAZOO Racing May 13, 2024 13:56 JST
| DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion May 10, 2024 18:13 JST
| Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku" May 10, 2024 12:20 JST
| Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024 May 09, 2024 20:39 JST
| Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore May 09, 2024 19:00 JST
| Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India May 09, 2024 14:13 JST
| Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning May 09, 2024 10:41 JST
| Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance May 08, 2024 14:27 JST
|
More Latest Release >>
|